Biocompatibles looks for new partners after Johnson and Johnson pull-out
This article was originally published in Clinica
Executive Summary
Biocompatibles, one-time darling of the investment community, lost more than half its value last week on the news that one of its largest shareholders, Johnson & Johnson, will not be marketing its divYsio coated stent.